| Anna M Grassi, DO | |
|
301 S 7th Ave, Suite 245, West Reading, PA 19611-1410 | |
| (484) 628-7900 | |
| (610) 685-5264 |
| Full Name | Anna M Grassi |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 12 Years |
| Location | 301 S 7th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255691457 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | OS018148 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
A long-term study has revealed a link between a faster heart rate and the risk of a heart attack and the researchers say that heart disease patients with a pulse of more than 70 beats a minute are most at risk.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
"It's one small piece of health care reform, but it's a big deal for medical schools and doctor's offices: forgiving the student loans of doctors who choose primary care," the Minneapolis Star Tribune reports.
A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works.
› Verified 2 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
A long-term study has revealed a link between a faster heart rate and the risk of a heart attack and the researchers say that heart disease patients with a pulse of more than 70 beats a minute are most at risk.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
"It's one small piece of health care reform, but it's a big deal for medical schools and doctor's offices: forgiving the student loans of doctors who choose primary care," the Minneapolis Star Tribune reports.
A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna M Grassi, DO Po Box 13579, Reading, PA 19612-3579 Ph: () - | Anna M Grassi, DO 301 S 7th Ave, Suite 245, West Reading, PA 19611-1410 Ph: (484) 628-7900 |
News Archive
A long-term study has revealed a link between a faster heart rate and the risk of a heart attack and the researchers say that heart disease patients with a pulse of more than 70 beats a minute are most at risk.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
"It's one small piece of health care reform, but it's a big deal for medical schools and doctor's offices: forgiving the student loans of doctors who choose primary care," the Minneapolis Star Tribune reports.
A Duke University Medical Center researcher who spent years looking for the signals that prompt the brain to form new connections between neurons has found one that may explain precisely how a well-known drug for epilepsy and pain actually works.
› Verified 2 days ago
Tej Ganti, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Dr. Jean M Payer, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, Suite 245, West Reading, PA 19611 Phone: 610-374-2214 Fax: 610-685-5264 | |
Kirthik Nathan Parthasarathy, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6th Avenue & Spruce Street, West Reading, PA 19611 Phone: 484-628-8614 | |
Sarah Payne, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8614 | |
Bahman Sadeghi, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8614 | |
Alfred George Neubert, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6th Ave & Spruce St, West Reading, PA 19611 Phone: 610-988-8446 | |
Angel Marquez, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 |